SGMT

9.0805.61%
DA

David A. Happel

CEO, President & Director

Mr. David A. Happel, also known as Dave, has been Chief Executive Officer and Director of Sagimet Biosciences Inc. since October 2022 and serves as its President since October 2022. From March 2020 through October 2022, he was president and chief executive officer of Cognoa Inc. Mr. Happel served as Chief Executive Officer of Chrono Therapeutics Inc. since February 2018 and served as its President and Director. He also previously served in senior management roles at Horizon Therapeutics, Raptor Pharma, Allergen Research Corporation, Dynavax Technologies and Chiron Corporation. Mr. Happel has served as a director of Currax Pharmaceuticals LLC since 2020. He brings extensive experience in the start-up biotech space and has a proven track record of developing and executing corporate business strategies, raising private and public capital and negotiating M&A transactions. Mr. Happel’s expertise lies in commercialization, having successfully launched and commercialized numerous products across the medical space, experience he intends to draw upon at Cognoa. He also specializes in rare disease early-stage development and operations. Mr. Happel served as Executive Vice President of Commercial Development & Strategy at Horizon Pharma Public Ltd Company since September 1, 2017 until February 2018. Mr. Happel served as an Executive Vice President of Global Orphan Business Unit at Horizon Pharma plc since October 2016 until September 1, 2017. Mr. Happel joined Horizon Pharma in October 2016. Mr. Happel served as the Chief Commercial Officer of Raptor Pharmaceuticals Corp. since October 2014. Mr. Happel served as the Chief Commercial Officer of Allergen Research Corporation, where he led global commercial and corporate development. Prior to Allergen, he served as Vice President of Global Sales & Marketing at Dynavax Technologies Corporation since July 10, 2012. He joined Dynavax from Dr. Reddy's Laboratories, where he focused on building a proprietary products business for North America. He served as Chief Commercial Officer of Aerovance, Inc. since December 18, 2006 and also served as its Executive Vice President. He has extensive experience in the healthcare industry into the role with dedicated to developing and commercializing treatments for rare diseases. Mr. Happel has extensive experience in the biotech and pharmaceutical industry, including senior level leadership roles in global marketing, sales, product management and commercial operations. Prior to joining Aerovance Inc., Mr. Happel served in Executive positions with Chiron Corp.’s biopharmaceuticals division and as Vice President of pulmonology, he led the highly successful pulmonary business unit, including the sales and marketing functions for TOBI tobramycin inhalation solution for the treatment of patients living with cystic fibrosis. He served as Chiron Corporation at InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI for cystic fibrosis and ACTIMMUNE® for the treatment of multiple orphan diseases. Earlier in his career, he served as a Senior Director, Sales and Marketing for Intermune, Inc.'s pulmonary business unit, where he launched its U.S. commercial initiatives for Actimmune(R). In addition, he held several product marketing and sales positions on a global basis with Parke-Davis/Pfizer Inc. Mr. Happel received his B.A. in Chemistry from Indiana University and an M.B.A. in Marketing from Indiana State University.

Positions